<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29104624</article-id><article-id pub-id-type="pmc">5658686</article-id><article-id pub-id-type="doi">10.3892/etm.2017.5088</article-id><article-id pub-id-type="publisher-id">ETM-0-0-5088</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Smart watch-based coaching with tiotropium and olodaterol ameliorates physical activity in patients with chronic obstructive pulmonary disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hataji</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5088">1</xref></contrib><contrib contrib-type="author"><name><surname>Nishii</surname><given-names>Yoichi</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5088">1</xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>Kentaro</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5088">1</xref></contrib><contrib contrib-type="author"><name><surname>Sakaguchi</surname><given-names>Tadashi</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5088">1</xref></contrib><contrib contrib-type="author"><name><surname>Saiki</surname><given-names>Haruko</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5088">1</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Yuta</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5088">1</xref></contrib><contrib contrib-type="author"><name><surname>D'Alessandro-Gabazza</surname><given-names>Corina</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-5088">2</xref></contrib><contrib contrib-type="author"><name><surname>Fujimoto</surname><given-names>Hajime</given-names></name><xref ref-type="aff" rid="af3-etm-0-0-5088">3</xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>Tetsu</given-names></name><xref ref-type="aff" rid="af3-etm-0-0-5088">3</xref></contrib><contrib contrib-type="author"><name><surname>Gabazza</surname><given-names>Esteban C.</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-5088">2</xref><xref rid="c1-etm-0-0-5088" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Taguchi</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="af4-etm-0-0-5088">4</xref></contrib></contrib-group><aff id="af1-etm-0-0-5088"><label>1</label>Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie 515-8544, Japan</aff><aff id="af2-etm-0-0-5088"><label>2</label>Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan</aff><aff id="af3-etm-0-0-5088"><label>3</label>Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan</aff><aff id="af4-etm-0-0-5088"><label>4</label>Mental and Physical Health Center, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan</aff><author-notes><corresp id="c1-etm-0-0-5088"><italic>Correspondence to</italic>: Professor Esteban C. Gabazza, Department of Immunology, Mie University Faculty and Graduate School of Medicine, Edobashi 2-174, Tsu, Mie 514-8507, Japan, E-mail: <email>gabazza@clin.medic.mie-u.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>01</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>9</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>14</volume><issue>5</issue><fpage>4061</fpage><lpage>4064</lpage><history><date date-type="received"><day>23</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Hataji et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>Combined therapy with tiotropium and olodaterol notably improves parameters of lung function and quality of life in patients with chronic obstructive pulmonary disease (COPD) compared to mono-components; however, its effect on physical activity is unknown. The present study evaluated whether combination therapy affects daily physical performance in patients with COPD under a smart watch-based encouragement program. This was a non-blinded clinical trial with no randomization or placebo control. A total of 20 patients with COPD were enrolled in the present study. The patients carried an accelerometer for 4 weeks; they received no therapy during the first 2 weeks but they were treated with combined tiotropium and olodaterol under a smart watch-based encouragement program for the last 2 weeks. The pulmonary function test, COPD assessment test, 6-min walk distance and parameters of physical activity were significantly improved (P&#x0003c;0.05) by combination therapy under smart watch-based coaching compared with values prior to treatment. To the best of our knowledge, the present study for the first time provides evidence that smart watch-based coaching in combination with tiotropium and olodaterol may improve daily physical activity in chronic obstructive pulmonary disease.</p></abstract><kwd-group><kwd>chronic obstructive pulmonary disease</kwd><kwd>long-acting &#x003b2;2-agonist</kwd><kwd>long-acting muscarinic antagonist</kwd><kwd>physical activity</kwd><kwd>smart watch</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In general, habitual and daily physical activity has been associated with a healthy status, prolonged life expectance and reduced prevalence of chronic diseases (<xref rid="b1-etm-0-0-5088" ref-type="bibr">1</xref>,<xref rid="b2-etm-0-0-5088" ref-type="bibr">2</xref>). The grade of physical activity is also an important determinant factor of the clinical condition, progression and outcome in patients with chronic obstructive pulmonary disease (COPD) (<xref rid="b3-etm-0-0-5088" ref-type="bibr">3</xref>&#x02013;<xref rid="b5-etm-0-0-5088" ref-type="bibr">5</xref>). Patients with COPD with reduced physical activity have been demonstrated to have a rapid decline of pulmonary function, weakened and reduced limb muscle mass, frequent hospitalizations, poor quality of life and worse prognosis compared to patients with an active lifestyle (<xref rid="b3-etm-0-0-5088" ref-type="bibr">3</xref>&#x02013;<xref rid="b5-etm-0-0-5088" ref-type="bibr">5</xref>). Therefore, one of the main goals of COPD therapy is to increase the physical participation during daily life activity.</p><p>The long-acting muscarinic antagonists (LAMAs) and the long-acting &#x003b2;2-agonists (LABAs) are bronchodilators that are presently recommended in clinical practice (<xref rid="b6-etm-0-0-5088" ref-type="bibr">6</xref>,<xref rid="b7-etm-0-0-5088" ref-type="bibr">7</xref>). The LAMA tiotropium and the LABA olodaterol, that require only once-a-day administration, have been indicated to be very effective at improving the clinical outcome in COPD (<xref rid="b6-etm-0-0-5088" ref-type="bibr">6</xref>,<xref rid="b7-etm-0-0-5088" ref-type="bibr">7</xref>). As inhaled bronchodilators are currently the mainstay for long-term maintenance therapy of patients with COPD with moderate to severe disease and combination of bronchodilators with different mechanisms of action may enhance efficacy and reduce the possibility of adverse events, clinical trials with combination of a fixed dose of tiotropium and olodaterol have been conducted, and the results have revealed significant improvement in parameters of pulmonary function tests and quality of life in comparison with each mono-component drug (<xref rid="b6-etm-0-0-5088" ref-type="bibr">6</xref>&#x02013;<xref rid="b9-etm-0-0-5088" ref-type="bibr">9</xref>). However, whether this combined therapy may ameliorate the physical performance of patients with COPD remains elusive.</p><p>In the present investigation, the physical activity of patients with COPD before and after a combined therapy with tiotropium and olodaterol under a smart watch-based encouragement system was evaluated and compared.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><sec><title/><sec><title>Patients</title><p>A total of 20 patients with COPD (18 males and 2 females; mean age, 70.3&#x000b1;6.4 years; age range, 58&#x02013;83 years) with stable disease followed up at the Respiratory Center of Matsusaka Municipal Hospital (Matsusaka, Japan) from February-April 2016 were enrolled in the present study. COPD was diagnosed following the criteria of the American Thoracic Society (<xref rid="b9-etm-0-0-5088" ref-type="bibr">9</xref>). A volume-type spirometer (Super Spiro, DISCOM-21FX III; Chest M.I., Inc., Tokyo, Japan) was used to measure lung function parameters, including forced expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC). The protocol and criteria for the 6-min walk test (6MWT) and the COPD Assessment Test (CAT) were previously described (<xref rid="b10-etm-0-0-5088" ref-type="bibr">10</xref>,<xref rid="b11-etm-0-0-5088" ref-type="bibr">11</xref>). All subjects provided informed consent prior to initiation of the study. The protocol was approved by the Matsusaka Municipal Hospital Ethics Board for Clinical Investigation (approval no. 150304-2-2) and the study was undertaken following the principles of the Declaration of Helsinki (clinical registration no. UMIN 23583). <xref rid="tI-etm-0-0-5088" ref-type="table">Table I</xref> summarizes the clinical and functional parameters of the subjects. All eligible patients were ex-smokers and none of them were receiving any smoking cessation pharmacotherapy, home oxygen therapy or pulmonary rehabilitation.</p></sec><sec><title>Study protocol</title><p>All patients with COPD carried a Lifecorder (Suzuken Co., Ltd., Nagoya, Japan), a uniaxial accelerometer sensor, fixed to their belts during the entire study period of 4 weeks in order to record the daily physical activity, including the number of steps, energy expenditure and the walking distance. A smart watch (Apple, Inc., Cupertino, CA, USA) worn by the patients during the 4-week study was used to encourage exercise performance. A moderate grade of physical activity (number of steps) was set up in the smart watch based on the height and weight of the patients. When the patient's physical activity was below or near the established goal, the smart watch vibrated and provided real-time motivational cues in the form of text messages, for example &#x02018;time to stand up and stay active for 1 min&#x02019; or &#x02018;you are almost there.&#x02019; The patients were instructed to take fixed-dose combination of tiotropium (5 &#x000b5;g) + olodaterol (5 &#x000b5;g) once daily using the Respimat inhaler (Spiolto<sup>&#x02122;</sup>, Respimat; Boehringer Ingelheim, am Rhein, Germany) during the last 2 weeks of the study period. Rescue therapy with short-acting &#x003b2; agonist was not used during the study. All patients received sufficient instruction on how to fix and use the devices in the morning when they woke up and to remove them at night.</p></sec><sec><title>Statistical analysis</title><p>Data were expressed as the mean &#x000b1; standard deviation. The non-parametric Wilcoxon rank test was employed to assess the difference among the means of two variables. Statistical analyses were performed using the StatView 4.5 package for Macintosh (Abacus Concepts, Piscataway, NJ, USA). P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Lung function and symptomatic parameters</title><p>Comparative assessment of pulmonary function tests before and after treatment with combination therapy demonstrated a significant increase of FEV1 and FVC after 2 weeks (P&#x0003c;0.001; <xref rid="f1-etm-0-0-5088" ref-type="fig">Fig. 1</xref>) in all treated patients. In addition to spirometric findings, symptom burden indicators, such as CAT, have also been recently recommended by the Global Initiative for COPD for follow-up and management of patients with COPD (<xref rid="b7-etm-0-0-5088" ref-type="bibr">7</xref>). The CAT score was significantly improved in all patients by combination therapy compared to values before initiation of the treatment (P&#x0003c;0.05; <xref rid="f2-etm-0-0-5088" ref-type="fig">Fig. 2</xref>).</p></sec><sec><title>Physical activity parameters</title><p>The distance walked during the 6MWT was significantly increased in all patients following treatment compared to that before starting the combination therapy with tiotropium and olodaterol (P&#x0003c;0.01; <xref rid="f2-etm-0-0-5088" ref-type="fig">Fig. 2</xref>). The number of steps, energy expenditure expressed in kilocalories and the metabolic equivalent of task (MET) from 1&#x02013;9 METs (total activity), 1&#x02013;3 METs (low-intensity activity), 4&#x02013;6 METs (moderate-intensity activity) and 7&#x02013;9 METs (high-intensity activity), were measured using the Lifecorder. The mean number of steps and the mean energy expended in kilocalories for all patients were significantly increased (P&#x0003c;0.01 and P&#x0003c;0.05, respectively) following treatment compared to the mean values before treatment (<xref rid="f3-etm-0-0-5088" ref-type="fig">Fig. 3</xref>). The total, low-intensity and moderate-intensity activities were significantly higher (P&#x0003c;0.01, P&#x0003c;0.05 and P&#x0003c;0.05, respectively) following combination therapy than values before therapy (<xref rid="f4-etm-0-0-5088" ref-type="fig">Fig. 4</xref>). No significant difference was observed in physical activity parameters when patients were under smart watch-based encouragement but without receiving combination therapy with bronchodilators (data not shown).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>To the best of our knowledge, the present study demonstrated for the first time that combination therapy with tiotropium + olodaterol administered once daily significantly ameliorates physical activity parameters, including 6-min walking distance, number of steps, energy expenditure and metabolic equivalent of task, in patients with COPD.</p><p>Accumulating evidence supports the critical importance of enhancing physical activity in COPD (<xref rid="b12-etm-0-0-5088" ref-type="bibr">12</xref>). One strong illustrative example is the reported beneficial effects of the formal pulmonary rehabilitation program on health status, exercise performance and life expectancy of patients with COPD (<xref rid="b13-etm-0-0-5088" ref-type="bibr">13</xref>,<xref rid="b14-etm-0-0-5088" ref-type="bibr">14</xref>). Unfortunately, pulmonary rehabilitation is not accessible to all patients as it is costly, time-consuming and requires an interdisciplinary professional team and special facilities (<xref rid="b15-etm-0-0-5088" ref-type="bibr">15</xref>&#x02013;<xref rid="b17-etm-0-0-5088" ref-type="bibr">17</xref>). Therefore, alternative methods, including pharmacological and non-pharmacological approaches, have been undertaken to encourage physical activity in patients with COPD (<xref rid="b18-etm-0-0-5088" ref-type="bibr">18</xref>). LABA and LAMA are included among the pharmacological approaches. However, despite the beneficial effects of LABA or LAMA on subjective symptoms, pulmonary function and quality of life, the impact of LABA or LAMA on daily life physical activity in patients with COPD is controversial (<xref rid="b19-etm-0-0-5088" ref-type="bibr">19</xref>,<xref rid="b20-etm-0-0-5088" ref-type="bibr">20</xref>). Short-term studies have demonstrated amelioration of physical activity by individual bronchodilators; however, long-term clinical trials have shown no effect (<xref rid="b19-etm-0-0-5088" ref-type="bibr">19</xref>,<xref rid="b20-etm-0-0-5088" ref-type="bibr">20</xref>). Non-pharmacological incentives, including the use of pedometers, phone calls, web-based support or smartphone-based activity stimulators, have also been trialled but without any conclusive results (<xref rid="b21-etm-0-0-5088" ref-type="bibr">21</xref>&#x02013;<xref rid="b24-etm-0-0-5088" ref-type="bibr">24</xref>).</p><p>In the present study, to further address this question, a combined pharmacological and non-pharmacological approach was used to motivate physical activity in patients with COPD. In the present study, the patients were encouraged to be physically active by a smart watch-based coaching system during the period they were being treated with a combination of tiotropium + olodaterol. Through this dual approach using a smart watch-based alarm and a drug containing both LAMA + LABA, the patients demonstrated significant improvement in daily life physical activity.</p><p>In conclusion, the present study demonstrated that a smart watch-based coaching system in combination with tiotropium and olodaterol has a favorable impact on patients with stable COPD by increasing their physical activity level.</p></sec></body><back><ack><title>Acknowledgements</title><p>OH has received honorarium for lectures from Boehringer Ingelheim.</p></ack><ref-list><title>References</title><ref id="b1-etm-0-0-5088"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>HW</given-names><suffix>III</suffix></name><name><surname>Craig</surname><given-names>CL</given-names></name><name><surname>Lambert</surname><given-names>EV</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Alkandari</surname><given-names>JR</given-names></name><name><surname>Leetongin</surname><given-names>G</given-names></name><name><surname>Kahlmeier</surname><given-names>S</given-names></name></person-group><article-title>Lancet Physical Activity Series Working Group: The pandemic of physical inactivity: Global action for public health</article-title><source>Lancet</source><volume>380</volume><fpage>294</fpage><lpage>305</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60898-8</pub-id><pub-id pub-id-type="pmid">22818941</pub-id></element-citation></ref><ref id="b2-etm-0-0-5088"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>IM</given-names></name><name><surname>Shiroma</surname><given-names>EJ</given-names></name><name><surname>Lobelo</surname><given-names>F</given-names></name><name><surname>Puska</surname><given-names>P</given-names></name><name><surname>Blair</surname><given-names>SN</given-names></name><name><surname>Katzmarzyk</surname><given-names>PT</given-names></name></person-group><article-title>Lancet Physical Activity Series Working Group: Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy</article-title><source>Lancet</source><volume>380</volume><fpage>219</fpage><lpage>229</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61031-9</pub-id><pub-id pub-id-type="pmid">22818936</pub-id></element-citation></ref><ref id="b3-etm-0-0-5088"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benzo</surname><given-names>RP</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Farrell</surname><given-names>MH</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Ries</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Wise</surname><given-names>R</given-names></name><name><surname>Make</surname><given-names>B</given-names></name><name><surname>Sciurba</surname><given-names>F</given-names></name></person-group><article-title>NETT Research Group: Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease</article-title><source>Respiration</source><volume>80</volume><fpage>10</fpage><lpage>18</lpage><year>2010</year><pub-id pub-id-type="doi">10.1159/000296504</pub-id><pub-id pub-id-type="pmid">20234126</pub-id></element-citation></ref><ref id="b4-etm-0-0-5088"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Rio</surname><given-names>F</given-names></name><name><surname>Rojo</surname><given-names>B</given-names></name><name><surname>Casitas</surname><given-names>R</given-names></name><name><surname>Lores</surname><given-names>V</given-names></name><name><surname>Madero</surname><given-names>R</given-names></name><name><surname>Romero</surname><given-names>D</given-names></name><name><surname>Galera</surname><given-names>R</given-names></name><name><surname>Villasante</surname><given-names>C</given-names></name></person-group><article-title>Prognostic value of the objective measurement of daily physical activity in patients with COPD</article-title><source>Chest</source><volume>142</volume><fpage>338</fpage><lpage>346</lpage><year>2012</year><pub-id pub-id-type="doi">10.1378/chest.11-2014</pub-id><pub-id pub-id-type="pmid">22281798</pub-id></element-citation></ref><ref id="b5-etm-0-0-5088"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitta</surname><given-names>F</given-names></name><name><surname>Troosters</surname><given-names>T</given-names></name><name><surname>Probst</surname><given-names>VS</given-names></name><name><surname>Spruit</surname><given-names>MA</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Gosselink</surname><given-names>R</given-names></name></person-group><article-title>Physical activity and hospitalization for exacerbation of COPD</article-title><source>Chest</source><volume>129</volume><fpage>536</fpage><lpage>544</lpage><year>2006</year><pub-id pub-id-type="doi">10.1378/chest.129.3.536</pub-id><pub-id pub-id-type="pmid">16537849</pub-id></element-citation></ref><ref id="b6-etm-0-0-5088"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Maltais</surname><given-names>F</given-names></name><name><surname>Abrahams</surname><given-names>R</given-names></name><name><surname>Bjermer</surname><given-names>L</given-names></name><name><surname>Derom</surname><given-names>E</given-names></name><name><surname>Ferguson</surname><given-names>G</given-names></name><name><surname>Fle&#x0017e;ar</surname><given-names>M</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>J</given-names></name><name><surname>McGarvey</surname><given-names>L</given-names></name><name><surname>Pizzichini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2&#x02013;4)</article-title><source>Eur Respir J</source><volume>45</volume><fpage>969</fpage><lpage>979</lpage><year>2015</year><pub-id pub-id-type="doi">10.1183/09031936.00136014</pub-id><pub-id pub-id-type="pmid">25573406</pub-id></element-citation></ref><ref id="b7-etm-0-0-5088"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Fle&#x0017e;ar</surname><given-names>M</given-names></name><name><surname>Korn</surname><given-names>S</given-names></name><name><surname>Korducki</surname><given-names>L</given-names></name><name><surname>Gr&#x000f6;nke</surname><given-names>L</given-names></name><name><surname>Abrahams</surname><given-names>R</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name></person-group><article-title>Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: A post hoc analysis</article-title><source>Adv Ther</source><volume>32</volume><fpage>523</fpage><lpage>536</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s12325-015-0218-0</pub-id><pub-id pub-id-type="pmid">26112656</pub-id></element-citation></ref><ref id="b8-etm-0-0-5088"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>LD</given-names></name><name><surname>Scanlon</surname><given-names>PD</given-names></name><name><surname>Yates</surname><given-names>JC</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Bakke</surname><given-names>P</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Coxson</surname><given-names>HO</given-names></name><name><surname>Crim</surname><given-names>C</given-names></name><etal/></person-group><article-title>Changes in forced expiratory volume in 1 sec over time in COPD</article-title><source>N Engl J Med</source><volume>365</volume><fpage>1184</fpage><lpage>1192</lpage><year>2011</year><pub-id pub-id-type="doi">10.1056/NEJMoa1105482</pub-id><pub-id pub-id-type="pmid">21991892</pub-id></element-citation></ref><ref id="b9-etm-0-0-5088"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Buist</surname><given-names>SA</given-names></name><name><surname>Calverley</surname><given-names>P</given-names></name><name><surname>Fukuchi</surname><given-names>Y</given-names></name><name><surname>Jenkins</surname><given-names>C</given-names></name><name><surname>Rodriguez-Roisin</surname><given-names>R</given-names></name><name><surname>van Weel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title><source>Am J Respir Crit Care Med</source><volume>176</volume><fpage>532</fpage><lpage>555</lpage><year>2007</year><pub-id pub-id-type="doi">10.1164/rccm.200703-456SO</pub-id><pub-id pub-id-type="pmid">17507545</pub-id></element-citation></ref><ref id="b10-etm-0-0-5088"><label>10</label><element-citation publication-type="journal"><article-title>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: Guidelines for the six-minute walk test</article-title><source>Am J Respir Crit Care Med</source><volume>166</volume><fpage>111</fpage><lpage>117</lpage><year>2002</year><pub-id pub-id-type="doi">10.1164/ajrccm.166.1.at1102</pub-id><pub-id pub-id-type="pmid">12091180</pub-id></element-citation></ref><ref id="b11-etm-0-0-5088"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>AJ</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Patel</surname><given-names>AR</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><article-title>Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations</article-title><source>Am J Respir Crit Care Med</source><volume>185</volume><fpage>1218</fpage><lpage>1224</lpage><year>2012</year><pub-id pub-id-type="doi">10.1164/rccm.201110-1843OC</pub-id><pub-id pub-id-type="pmid">22281834</pub-id></element-citation></ref><ref id="b12-etm-0-0-5088"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaes</surname><given-names>AW</given-names></name><name><surname>Garcia-Aymerich</surname><given-names>J</given-names></name><name><surname>Marott</surname><given-names>JL</given-names></name><name><surname>Benet</surname><given-names>M</given-names></name><name><surname>Groenen</surname><given-names>MT</given-names></name><name><surname>Schnohr</surname><given-names>P</given-names></name><name><surname>Franssen</surname><given-names>FM</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Spruit</surname><given-names>MA</given-names></name></person-group><article-title>Changes in physical activity and all-cause mortality in COPD</article-title><source>Eur Respir J</source><volume>44</volume><fpage>1199</fpage><lpage>1209</lpage><year>2014</year><pub-id pub-id-type="doi">10.1183/09031936.00023214</pub-id><pub-id pub-id-type="pmid">25063247</pub-id></element-citation></ref><ref id="b13-etm-0-0-5088"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>JW</given-names></name><name><surname>Hogg</surname><given-names>L</given-names></name><name><surname>Nolan</surname><given-names>J</given-names></name><name><surname>Jefford</surname><given-names>H</given-names></name><name><surname>Grant</surname><given-names>A</given-names></name><name><surname>Lord</surname><given-names>VM</given-names></name><name><surname>Falzon</surname><given-names>C</given-names></name><name><surname>Garrod</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Polkey</surname><given-names>MI</given-names></name><etal/></person-group><article-title>The COPD assessment test (CAT): Response to pulmonary rehabilitation. A multicentre, prospective study</article-title><source>Thorax</source><volume>66</volume><fpage>425</fpage><lpage>429</lpage><year>2011</year><pub-id pub-id-type="doi">10.1136/thx.2010.156372</pub-id><pub-id pub-id-type="pmid">21398686</pub-id></element-citation></ref><ref id="b14-etm-0-0-5088"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacasse</surname><given-names>Y</given-names></name><name><surname>Goldstein</surname><given-names>R</given-names></name><name><surname>Lasserson</surname><given-names>TJ</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name></person-group><article-title>Pulmonary rehabilitation for chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst Rev: CD003793</source><year>2006</year><pub-id pub-id-type="doi">10.1002/14651858.CD003793.pub2</pub-id></element-citation></ref><ref id="b15-etm-0-0-5088"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>ZuWallack</surname><given-names>R</given-names></name></person-group><article-title>Pulmonary rehabilitation for management of chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><volume>360</volume><fpage>1329</fpage><lpage>1335</lpage><year>2009</year><pub-id pub-id-type="doi">10.1056/NEJMct0804632</pub-id><pub-id pub-id-type="pmid">19321869</pub-id></element-citation></ref><ref id="b16-etm-0-0-5088"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nici</surname><given-names>L</given-names></name><name><surname>Donner</surname><given-names>C</given-names></name><name><surname>Wouters</surname><given-names>E</given-names></name><name><surname>Zuwallack</surname><given-names>R</given-names></name><name><surname>Ambrosino</surname><given-names>N</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Carone</surname><given-names>M</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Engelen</surname><given-names>M</given-names></name><name><surname>Fahy</surname><given-names>B</given-names></name><etal/></person-group><article-title>American thoracic society/european respiratory society statement on pulmonary rehabilitation</article-title><source>Am J Respir Crit Care Med</source><volume>173</volume><fpage>1390</fpage><lpage>1413</lpage><year>2006</year><pub-id pub-id-type="doi">10.1164/rccm.200508-1211ST</pub-id><pub-id pub-id-type="pmid">16760357</pub-id></element-citation></ref><ref id="b17-etm-0-0-5088"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yohannes</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>R</given-names></name><name><surname>Lowe</surname><given-names>D</given-names></name><name><surname>Pursey</surname><given-names>N</given-names></name><name><surname>Buckingham</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name></person-group><article-title>Pulmonary rehabilitation in the United Kingdom</article-title><source>Chron Respir Dis</source><volume>8</volume><fpage>193</fpage><lpage>199</lpage><year>2011</year><pub-id pub-id-type="doi">10.1177/1479972311413400</pub-id><pub-id pub-id-type="pmid">21724662</pub-id></element-citation></ref><ref id="b18-etm-0-0-5088"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>AH</given-names></name></person-group><article-title>Exercise adherence in patients with chronic obstructive pulmonary disease: An exploration of motivation and goals</article-title><source>Rehabil Nurs</source><volume>32</volume><fpage>104</fpage><lpage>110</lpage><year>2007</year><pub-id pub-id-type="doi">10.1002/j.2048-7940.2007.tb00161.x</pub-id><pub-id pub-id-type="pmid">17514994</pub-id></element-citation></ref><ref id="b19-etm-0-0-5088"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>Y</given-names></name><name><surname>Minami</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Ogata</surname><given-names>Y</given-names></name><name><surname>Koba</surname><given-names>T</given-names></name><name><surname>Futami</surname><given-names>S</given-names></name><name><surname>Komuta</surname><given-names>K</given-names></name></person-group><article-title>Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease</article-title><source>Int J Chron Obstruct Pulmon Dis</source><volume>10</volume><fpage>439</fpage><lpage>444</lpage><year>2015</year><pub-id pub-id-type="pmid">25767381</pub-id></element-citation></ref><ref id="b20-etm-0-0-5088"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watz</surname><given-names>H</given-names></name><name><surname>Krippner</surname><given-names>F</given-names></name><name><surname>Kirsten</surname><given-names>A</given-names></name><name><surname>Magnussen</surname><given-names>H</given-names></name><name><surname>Vogelmeier</surname><given-names>C</given-names></name></person-group><article-title>Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease-a randomized, multicenter, double-blind, placebo-controlled study</article-title><source>BMC Pulm Med</source><volume>14</volume><fpage>158</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1471-2466-14-158</pub-id><pub-id pub-id-type="pmid">25280934</pub-id></element-citation></ref><ref id="b21-etm-0-0-5088"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>L</given-names></name><name><surname>Horta</surname><given-names>P</given-names></name><name><surname>Espinoza</surname><given-names>J</given-names></name><name><surname>Aguilera</surname><given-names>M</given-names></name><name><surname>Balmaceda</surname><given-names>N</given-names></name><name><surname>Castro</surname><given-names>A</given-names></name><name><surname>Ruiz</surname><given-names>M</given-names></name><name><surname>D&#x000ed;az</surname><given-names>O</given-names></name><name><surname>Hopkinson</surname><given-names>NS</given-names></name></person-group><article-title>Pedometers to enhance physical activity in COPD: A randomised controlled trial</article-title><source>Eur Respir J</source><volume>45</volume><fpage>347</fpage><lpage>354</lpage><year>2015</year><pub-id pub-id-type="doi">10.1183/09031936.00084514</pub-id><pub-id pub-id-type="pmid">25261324</pub-id></element-citation></ref><ref id="b22-etm-0-0-5088"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moy</surname><given-names>ML</given-names></name><name><surname>Weston</surname><given-names>NA</given-names></name><name><surname>Wilson</surname><given-names>EJ</given-names></name><name><surname>Hess</surname><given-names>ML</given-names></name><name><surname>Richardson</surname><given-names>CR</given-names></name></person-group><article-title>A pilot study of an Internet walking program and pedometer in COPD</article-title><source>Respir Med</source><volume>106</volume><fpage>1342</fpage><lpage>1350</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.rmed.2012.06.013</pub-id><pub-id pub-id-type="pmid">22795984</pub-id></element-citation></ref><ref id="b23-etm-0-0-5088"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabak</surname><given-names>M</given-names></name><name><surname>Brusse-Keizer</surname><given-names>M</given-names></name><name><surname>van der Valk</surname><given-names>P</given-names></name><name><surname>Hermens</surname><given-names>H</given-names></name><name><surname>Vollenbroek-Hutten</surname><given-names>M</given-names></name></person-group><article-title>A telehealth program for self-management of COPD exacerbations and promotion of an active lifestyle: A pilot randomized controlled trial</article-title><source>Int J Chron Obstruct Pulmon Dis</source><volume>9</volume><fpage>935</fpage><lpage>944</lpage><year>2014</year><pub-id pub-id-type="doi">10.2147/COPD.S60179</pub-id><pub-id pub-id-type="pmid">25246781</pub-id></element-citation></ref><ref id="b24-etm-0-0-5088"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wewel</surname><given-names>AR</given-names></name><name><surname>Gellermann</surname><given-names>I</given-names></name><name><surname>Schwertfeger</surname><given-names>I</given-names></name><name><surname>Morfeld</surname><given-names>M</given-names></name><name><surname>Magnussen</surname><given-names>H</given-names></name><name><surname>J&#x000f6;rres</surname><given-names>RA</given-names></name></person-group><article-title>Intervention by phone calls raises domiciliary activity and exercise capacity in patients with severe COPD</article-title><source>Respir Med</source><volume>102</volume><fpage>20</fpage><lpage>26</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.rmed.2007.08.011</pub-id><pub-id pub-id-type="pmid">17920825</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-etm-0-0-5088" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Pulmonary function test results before and after treatment with a combination of tiotropium + olodaterol. The FEV1 (1.38&#x000b1;0.40 vs. 1.58&#x000b1;0.47 l) and FVC (3.12&#x000b1;0.88 vs. 3.33&#x000b1;0.90 l) were significantly increased following therapy compared to before treatment. The mean &#x000b1; standard deviation of each group are presented adjacent to data points. Statistical analysis was performed by non-parametric Wilcoxon rank test. FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity.</p></caption><graphic xlink:href="etm-14-05-4061-g00"/></fig><fig id="f2-etm-0-0-5088" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>CAT and 6-min walk distance test results before and after treatment with a combination of tiotropium + olodaterol. CAT (13.0&#x000b1;5.7 vs. 9.2&#x000b1;6.9) was significantly decreased whereas the 6-min walk distance (459.9&#x000b1;64.3 vs. 489.2&#x000b1;53.6 m) was significantly increased following therapy compared to before treatment. The mean &#x000b1; standard deviation of each group are presented adjacent to data points. Statistical analysis was performed by non-parametric Wilcoxon rank test. CAT, chronic obstructive pulmonary disease assessment test.</p></caption><graphic xlink:href="etm-14-05-4061-g01"/></fig><fig id="f3-etm-0-0-5088" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Number of steps and energy expenditure in patients with chronic obstructive pulmonary disease before and after treatment with a combination of tiotropium + olodaterol. The number of daily steps (5.757&#x000b1;2.927 vs. 7.089&#x000b1;3.775 steps) and energy burned as calories (138.5&#x000b1;77.4 vs. 164.6&#x000b1;88.1 kilocalories) were significantly enhanced after therapy compared to values obtained before therapy. The mean &#x000b1; standard deviation of each group are presented adjacent to data points. Statistical analysis was performed by non-parametric Wilcoxon rank test.</p></caption><graphic xlink:href="etm-14-05-4061-g02"/></fig><fig id="f4-etm-0-0-5088" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>METs in patients with chronic obstructive pulmonary disease before and after treatment with a combination of tiotropium + olodaterol. The degree of physical activity expressed as MET was measured using a Lifecorder. The total (1&#x02013;9 METs; 47.935&#x000b1;9.345 vs. 50.445&#x000b1;8.944), low-intensity (1&#x02013;3 METs; 47.221&#x000b1;9.193 vs. 49.533&#x000b1;8.821) and moderate-intensity (4&#x02013;6 METs; 701&#x000b1;696 vs. 897&#x000b1;720) activities were significantly enhanced after combination therapy compared to values before initiation of therapy. There was no significant difference in high-intensity activity (13&#x000b1;15 vs. 15&#x000b1;20). The mean &#x000b1; standard deviation of each group are presented adjacent to data points. Statistical analysis was performed by non-parametric Wilcoxon rank test. METs, metabolic equivalent of tasks; NS, not significant.</p></caption><graphic xlink:href="etm-14-05-4061-g03"/></fig><table-wrap id="tI-etm-0-0-5088" orientation="portrait" position="float"><label>Table I.</label><caption><p>Baseline demography data of patients with chronic obstructive pulmonary disease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of patients</td><td align="center" valign="top" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="center" valign="top" rowspan="1" colspan="1">70.3&#x000b1;6.4 (58&#x02013;83)<sup><xref rid="tfn1-etm-0-0-5088" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male/female)</td><td align="center" valign="top" rowspan="1" colspan="1">18/2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index</td><td align="center" valign="top" rowspan="1" colspan="1">21.59&#x000b1;0.72</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Global Initiative for Chronic Obstructive</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lung Disease scale (n)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;2</td><td align="center" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;3</td><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC, 1</td><td align="center" valign="top" rowspan="1" colspan="1">3.12&#x000b1;0.88</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV1, 1</td><td align="center" valign="top" rowspan="1" colspan="1">1.38&#x000b1;0.40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV1 (% predicted)</td><td align="center" valign="top" rowspan="1" colspan="1">5.14&#x000b1;12.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV1/FVC, %</td><td align="center" valign="top" rowspan="1" colspan="1">45.5&#x000b1;10.2</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-5088"><label>a</label><p>Data are presented as the mean &#x000b1; standard deviation (range). FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec.</p></fn></table-wrap-foot></table-wrap></floats-group></article>